A head-to-head matchup between Johnson & Johnson combination and AstraZeneca’s drug, Tagrisso as a first-line treatment for non-small cell lung cancer has yielded J & J as the winner. In the MARIPOSA trial, J & J’s Rybrevant combined with its Yuhan partnered lazertinib has helped patients with locally advanced or metastatic EGFR mutated NSCLC survive longer in comparison with Tagrisso. These changes were statistically significant and clinically meaningful.
The MARIPOSA trial has enrolled over 1000 patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or substitution mutations. The interim analysis of data on overall survival for patients showed a favoring trend towards the combination therapy in comparison to AstraZeneca’s blockbuster drug. The analysts of the study said that the results were in line with their expectations and they will be closely watching details from the trial that J & J will present at the European Society of Medical Oncology Conference in October.
“Patients with treatment-naïve EGFR-mutated non-small cell lung cancer have historically been treated with EGFR TKIs, but these agents invariably lead to resistance and disease progression when used as monotherapy,” said Alexander Spira†, M.D., Ph.D., FACP, Director, Virginia Cancer Specialists Research Institute, and study investigator. “These promising data from MARIPOSA underscore the potential for the RYBREVANT and lazertinib regimen to advance treatment beyond TKI monotherapy.”
MARIPOSA marks the third RYBREVANT Phase 3 study to readout the PAPILLON and MARIPOSA-2. Janssen plans to submit these results at upcoming scientific congress.
“Positive topline results from the MARIPOSA study reinforce the potential of the RYBREVANT and lazertinib combination in frontline EGFR-mutated non-small cell lung cancer as a future standard of care,” remarked Peter Lebowitz, Janssen’s head of oncology.
The information shared in this blog is for educational purposes only. You should always consult your medical practitioner for any health issues.